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Abstract
Remote intracardiac hemodynamic monitoring is a growing area of interest to
help aid in the management of patients with chronic congestive heart failure. The
utility of remote hemodynamic monitoring has not previously been investigated
with a ventricular assist device population. We present two cases of patients
with ventricular assist devices in which we employed remote hemodynamic
monitoring data to aid in patient management.
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Introduction
Congestive heart failure is a major public health concern with high economic
burden on society and health care organizations. Heart failure is the leading
cause of hospitalization in patients above 65 years of age and is also associated
with a higher rate of readmissions1. Several strategies, both invasive and noninvasive, have been developed to predict the early signs of decompensation and
optimize management. Remote hemodynamic monitor systems have gained
momentum with enthusiasm intensifying after the results of the CardioMEMS™
(St. Jude Medical, Inc., St. Paul, MN) Heart Sensor Allows Monitoring of
Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients
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(CHAMPION) study, in which patients randomized to treatment guided by
pulmonary artery pressure data from the CardioMEMS™ device reduced heart
failure-related hospitalizations at six months2. Other devices, including
implantable left atrial pressure sensors with a subcutaneous antenna coil have
also been studied3.
Readmission rates after left ventricular device (LVAD) implantation are high4.
Hospital readmissions in LVAD patients occur at a rate of 1.5-2.5 per patient year
of support with heart failure representing a leading cause5-7. Persistent heart
failure early after LVAD implantation is common, occurring in up to 25% of
patients8. The usefulness of remote hemodynamic monitoring in patients with
LVAD is uncertain. It can theoretically aid in the management of patients with
LVADs by optimizing medications and pump parameters, thereby reducing
hospital readmissions. We present two cases of patients with LVADs whose
volume status we were able to manage in an outpatient setting by relying on
information made available by their respective implanted hemodynamic monitors.
Case 1
A 50-year-old, morbidly obese male with nonischemic, dilated cardiomyopathy
with a left ventricular ejection fraction (LVEF) < 15% and left ventricular internal
dimension in diastole of 9.1 cm was referred to our institution for management of
heart failure. He had persistent heart failure symptoms and poor quality of life,
despite optimal medical therapy including cardiac resynchronization therapy.
Evaluation for advanced heart failure therapy was initiated. Right ventricular size
and function were grossly normal. Baseline right-sided intracardiac filling
pressures were normal and mean pulmonary artery pressure measured 18
mmHg. The patient ultimately received a HeartWare® (HeartWare®,
Framingham, MA) LVAD in late January of 2014 and after a relatively benign
post-operative course, was discharged in two weeks. Pump speed was initially
set at 2300 revolutions per minute (RPM) and changed to 2500 RPMs prior to
discharge. Over the next 18 months, he had 15 admissions to our institution and
8 (53%) readmissions dealt with volume status, 5 for volume overload and 3 for
dehydration. Three additional changes to pump speed were made during this
period, ultimately maintained at 2900 RPMs.
Because of his body habitus, volume status was difficult to assess by physical
exam. In light of his tenuous volume status and frequent admissions, he was
referred for implantation of CardioMEMS™ performed in December of 2015.
Figure 1 displays the changes in the patient’s weights prior to implantation.
Figures 2-5 display the pulmonary artery pressures, the patient weights, LVAD
flows, and serum creatinine from December 2015 to March 2016 (after
CardioMEMS™ implantation).
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During this 3-month window, the medical regimen was adjusted as was the pump
speed based on hemodynamic data obtained. A total of eight occurrences of
medication changes were noted all of which involved adjustments to diuretic
dose. Exactly half the adjustments involved increasing the dose and half
decreasing the dose. Pump speed was increased to 3000 RPMs during this
period. The patient only had two admissions to our institution during this time,
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one for a concern of his implantable cardiac defibrillator firing and another for
evaluation of atypical chest pain. At present time, five months after
CardioMEMS implantation, he is doing well and has not had any futher
readmissions.

Case 2
A 66-year-old male with coronary artery disease status post 3-vessel coronary
artery bypass grafting and resultant ischemic cardiomyopathy with an LVEF <
15% was referred to our institution for advanced heart failure options. He had
recurrent hospitalizations for decompensated heart failure in the prior year. In
April of 2014, his pacemaker was upgraded to a CRT/BiV ICD and a left atrial
pressure-sensing device was implanted simultaneously as part of the Left Atrial
Pressure Monitoring to Optimize Heart Failure Therapy (LAPTOP-HF) study. He
developed progressively worsening heart failure with New York Heart Association
Class IV symptoms. Between September and December of 2015, he was
admitted for acutely decompensated heart failure 4 times with an average
hospital length of stay of 5 days. Given his end-stage ischemic cardiomyopathy,
a HeartMate II® (Thoractec) was implanted in late December of 2015.
Prior to implantation, the patient had significantly elevated right- and left-sided
filling pressures with a pulmonary capillary wedge pressure of 35 mmHg as well
as moderate pulmonary hypertension with a mean pulmonary artery pressure of
40 mmHg and a pulmonary vascular resistance of 2.8 Wood units despite
inotrope therapy. His post-operative course was complicated by respiratory
insufficiency requiring tracheostomy, healthcare associated pneumonia,
ventricular tachycardia, acute kidney injury, and blood-loss anemia. He slowly
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recovered and was subsequently discharged home with physical therapy. Left
atrial pressure readings from his previously implanted device were used to aid in
outpatient medications adjustments. Figures 6-7 display the left atrial pressure
readings and patient weights from January 2016 to March 2016.

During this brief 7-week period, the patient’s diuretic regimen was changed twice.
The initial change was an increase in the dose of his loop diuretic and the second
was the addition of a thiazide diuretic. During this period, device speed was
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changed and RPMs were increased from 8800 to 9400. Although the left atrial
pressure remains elevated, he is feeling well and has not have any
hospitalizations since the implantation of LVAD.

Discussion
Fluid retention remains a significant clinical concern in patients with end-stage
heart failure even after LVAD implantation. While an LVAD can provide full
mechanical support with systemic flows close to normal at rest, adjuvant diuretic
therapy is often still required. Decompensated heart failure while on a ventricular
assist support device is a known clinical entity9. This is likely related to the fact
that the LVAD is preload dependent and afterload sensitive10, 11.
Traditional noninvasive remote monitoring of heart failure patients requires
patients to comply with a stringent fluid restriction, daily weight monitoring, and
self-assessment of edema. Many patients lack self-care skills and literacy, which
makes it difficult for them to carry out these tasks. Compliance rates for even the
relatively simple task of weighing one’s self on a daily basis is poor12, 13. As a
result, many system practices rely on telemonitoring strategies. The National
Institute of Health TELE-HF study randomized 1,653 patients to standard care
versus telemonitoring using an automated telephone based system to collect
information. No significant difference between either group was found in terms of
all-cause mortality or heart failure-related readmissions14. The failure of similar
telemonitoring strategies has been replicated but studies do conflict15-17.
Noninvasive monitoring can be utilized in LVAD patients to monitor
hemodynamics and guide therapy to address fluid retention and symptoms of
decompensation. There is currently no data on the utility of these devices in
patients with durable circulatory support devices. The pitfalls of relying on patient
self-assessment or telemonitoring could be extrapolated to an LVAD patient
population although given the careful candidate selection and the need for close,
frequent follow-up, one would expect this group to be able to comply more
readily. It has been our experience that symptomatic fluid retention may persist
after LVAD implantation. Management based on intracardiac monitoring devices
is very promising in optimizing hemodynamics, improving quality of life, and
reducing hospitalizations.
The advantage of remote hemodynamic monitoring is the ability to identify
increases in intracardiac and pulmonary pressures before the development of
heart failure symptoms, sometimes days to weeks earlier14. The core question of
implantable hemodynamic monitoring systems is to determine whether frequent
assessment of intracardiac filling is better at reducing hospitalizations compared
to traditional tools. Adamson contends that understanding the pathophysiology
of the congestive cascade would aid in maintaining euvolemia, by highlighting
that increases in filling pressures precede the autonomic adaption to such
increases, and are subsequently followed by changes in weight and the
development of symptoms such as dyspnea and edema18.
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This principle is evidenced in both our cases. In case 1, the patient went from 8
volume status related admissions over an 18-month period to zero volume status
related admissions over a 5-month window. The second patient with a left atrial
pressure-sensing device had recently undergone LVAD implantation thus any
success of avoiding hospitalization for decompensated heart failure is
confounded. Despite this, we were still able to make adjustments to his
medication regimen. Figures 3 and 6 highlight the weight changes in both of our
patients during remote monitoring. Although the immediate impact from
adjustments to diuretic changes to weight is difficult to assess, we believe the
general downward trend in weight was related to our ability to make frequent
adjustments based on the remote intracardiac data available. Interestingly, the
scatter of data appreciable in Figure 2 would suggest that weight was not the
driver between medications adjustments.
There are several other potential advantages of remote hemodynamic monitoring
specific to the LVAD patient population. In pump thrombosis, increases in
pulmonary arterial pressures correlate with a rise in serum lactate
dehydrogenase (LDH)19. The potential to suspect the diagnosis of device
thrombosis remotely, before LDH is checked (which requires a clinic visit), or
more importantly, before the patient develops significant symptoms would be
invaluable.
Additionally, as LVADs are preload sensitive, remote intracardiac pressure
monitoring could allow for more accurate pump speed modifications and help
optimize the unloading of the left ventricle. In both our patients, we were able to
increase pump speed successfully while making changes to diuretic regimens. A
total of four changes to pump speed were made in the patient from case one
(including one prior to discharge of the recently placed LVAD) without the use of
remote hemodynamic monitoring while one change was made after implantation.
The use of invasive hemodynamics for guidance of the LVAD speed adjustment
was shown to be superior to a traditional echo-guided ramp test20.
Our second patient had pre-LVAD implantation pulmonary hypertension related
to intracardiac congestion. Secondary pulmonary hypertension, if severe
enough, is a contraindication for cardiac transplantation. The ability to monitor
pulmonary artery pressures and adjust medications accordingly would be more
comfortable for patients and help avoid exposing them to the risks of repeated
right heart catheterizations. This approach, in fact, may accelerate the
normalization of pulmonary vascular resistance, highlighting yet another
advantage of remote hemodynamic monitoring. In addition to recording
pulmonary artery pressures, the CardioMEMS™ system monitors heart rate and
dysrhythmias that could compromise LVAD function2. This was not an issue with
our patient. Given the multiple, distinct advantages of remote hemodynamic
monitoring, perhaps the trend of future LVAD models will include the ability to
measure left ventricular end diastolic pressures remotely. The idea of a “smart”
pump which can self-adjust pump speed based on built-in hemodynamic
pressure sensors has already started to circulate in the literature21.
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The ability of remote hemodynamic monitoring devices to accurately detect
elevated intracardiac filling pressures is unknown. Furthermore, the presence of
continuous-flow, mechanical support device within the left side of the heart may
reduce the sensitivity of pulmonary artery diastolic pressures. Nevertheless, the
potential advantages of remote hemodynamic monitoring the LVAD patient
population merits focus for future investigations.
In summary, decompensated heart failure and associated congestion remains
problematic for LVAD patients. Where traditional methods for assessing volume
status have proven unreliable, the utility and success of remote invasive
hemodynamic monitoring systems are clear and should have similar utility and
success in an LVAD patient. In our small cohort, such systems have proven
beneficial. Further studies including larger cases series and randomized control
data are needed to validate this claim.
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